Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas
Keisuke Kataoka,Hiroaki Miyoshi,Seiji Sakata,Akito Dobashi,Lucile Couronné,Yasunori Kogure,Yasuharu Sato,Kenji Nishida,Yuka Gion,Yuichi Shiraishi,Hiroko Tanaka,Kenichi Chiba,Yosaku Watatani,Nobuyuki Kakiuchi,Yusuke Shiozawa,Tetsuichi Yoshizato,Kenichi Yoshida,Hideki Makishima,Masashi Sanada,Masahiro Onozawa,Takanori Teshima,Yumiko Yoshiki,Tadao Ishida,Kenshi Suzuki,Kazuyuki Shimada,Akihiro Tomita,Motohiro Kato,Yasunori Ota,Koji Izutsu,Ayako Demachi-Okamura,Yoshiki Akatsuka,Satoru Miyano,Tadashi Yoshino,Philippe Gaulard,Olivier Hermine,Kengo Takeuchi,Koichi Ohshima,Seishi Ogawa
DOI: https://doi.org/10.1038/s41375-019-0380-5
Leukemia
Abstract:Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Predominantly causing a truncation of the 3'-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5%) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.